Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Appointed director
Asset disposition
Quarterly results
ProPhase Labs, Inc. (PRPH) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "ProPhase Labs Announces Financial Results for the Three Months Ended June 30, 2023 Company believes that the combined value of its five operating units exceeds its current market capitalization and that each unit has significant growth potential. Company highlights successful transition from reliance on COVID-19 testing to diversified growth opportunities in genomics, biotech, diagnostic and manufacturing. Transition marks the third transformation in the company’ s history as it invests in the key areas of personalized medicine. Company sheds more light on its strategic investments and with a key focus on its Nebula Genomics business."
06/29/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Navidea Biopharmaceuticals Rejects ProPhase Labs Offer To Acquire Certain Assets of Navidea Garden City, NY, June 29, 2023"
05/12/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2023 As revenue mix transitions, Company still achieves positive net income and significant adjusted EBITDA while acquiring and developing biotech, genomics and diagnostic assets with multi-billion-dollar potential Company highlights key strategic initiatives to grow underlying value in 2023 and beyond"
04/27/2023 ARS Form ARS - Annual Report to Security Holders:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/25/2023 8-K Quarterly results
04/06/2023 4 Morse Robert A. Jr. (CFO) has filed a Form 4 on ProPhase Labs, Inc.
Txns: Granted 50,000 options to buy @ $9, valued at $450k
04/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
04/05/2023 4 Karkus Ted William (CEO & CHAIRMAN) has filed a Form 4 on ProPhase Labs, Inc.
Txns: Gifted 50,000 shares @ $0
Gifted 50,000 shares @ $0
04/05/2023 SC 13D/A Karkus Ted William reports a 20.9% stake in ProPhase Labs, Inc.
04/04/2023 4 Karkus Ted William (CEO & CHAIRMAN) has filed a Form 4 on ProPhase Labs, Inc.
Txns: Gifted 100,000 shares @ $0
Granted 500,000 options to buy @ $9, valued at $4.5M
04/04/2023 SC 13D/A Karkus Ted William reports a 20.9% stake in ProPhase Labs, Inc.
03/29/2023 10-K Annual Report for the period ended December 31, 2022
03/28/2023 8-K Quarterly results
03/15/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "ProPhase Labs Announces New $6 Million Stock Repurchase Program Garden City, NY, March 15, 2023 --"
03/01/2023 8-K Quarterly results
02/22/2023 8-K Quarterly results
02/06/2023 8-K Quarterly results
02/02/2023 4 Karkus Ted William (CEO & CHAIRMAN) has filed a Form 4 on ProPhase Labs, Inc.
Txns: Paid exercise price by delivering 268,337 shares @ $8.18, valued at $2.2M
Exercised 500,000 options to buy @ $0.6, valued at $300k
02/02/2023 SC 13D/A Karkus Ted William reports a 21.6% stake in ProPhase Labs, Inc.
01/30/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "UNSECURED PROMISSORY NOTE and guaranty",
"COMMON STOCK PURCHASE WARRANT PROPHASE LABS, Inc. Warrant Shares: 76,000 Issue Date: January 27, 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, JXVII TRUST or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and on or prior to 5:00 p.m. on the five year anniversary of the Issue Date but not thereafter, to subscribe for and purchase from PROPHASE LABS, INC. , up to SEVENTY-SIX THOUSAND shares of the Company’ s common stock, par value $0.0005 per share . If the Termination Date is not a Business Day, then this Warrant may be exercised before 5:00 P.M. , on the next succeeding Business Day. The purchase price of one share of Common Stock under this W..."
01/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/17/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
01/13/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
01/05/2023 8-K Quarterly results
12/28/2022 8-K Quarterly results
12/20/2022 8-K Quarterly results
11/21/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
11/14/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/10/2022 8-K Quarterly results
11/08/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy